Meta-analysis of randomized trials: evaluation of benefit from gemcitabine-based combination chemotherapy applied in advanced pancreatic cancer

Table 1 Characteristics of 5 randomized trials comparing gemcitabine to gemcitabine plus platinum analog

Reference	Year	n	Treatment regimen	Stage IV (%)	Male (%)	PS 0–1 (%)
Louvet	2005	156	Gem 1000 mg/m² for 7 of 8 wks, then wkly for 3 of 4 wks	70	53	82
		157	Gem 1000 mg/m²/100 min d1 (FDR) + Oxaliplatin 100 mg/m² d2 q 2 wks	68	60	83
Poplin	2006	279	Gem 1000 mg/m² for 7 of 8 wks, then wkly for 3 of 4 wks (standard)	88	56	88
		277	Gem 1500 mg/m²/150 min q wk × 3 of 4 wks (FDR)		58
		276	Gem 1000 mg/m²/100 min d1 (FDR) + Oxaliplatin 100 mg/m² d2 q 2 wks		46
Heinemann	2006	97	Gem 1000 mg/m² for 3 of 4 wks	79	62	49*
		98	Gem 1000 mg/m² + Cisplatin 50 mg/m² q 2 wks	80	65	56*
Colucci	2002	54	Gem 1000 mg/m² for 7 of 8 wks, then wkly for 3 of 4 wks	54	50	med. KPS 70
		53	Gem 1000 mg/m² + Cisplatin 25 mg/m² for 6/7 wks	62	66	med. KPS 70
Viret	2004	41	Gem 1000 mg/m² for 7 of 8 wks, then wkly for 3 of 4 wks	78	na	83
		42	Gem 1000 mg/m² d1, 8, 15 + Cisplatin 75 mg/m² d15 q 4 wks	81	na	76

* KPS = 90–100%; PS = performance status; FDR = fixed dose rate; na = data not available;

ISSN: 1471-2407